The Phase I human medical trial for UCART19 is planned for 2015. Dr Mathieu Simon, MD, Executive Vice-President at Cellectis mentioned: ‘Thanks to the extremely positive in vivo proof concept outcomes for our flagship UCART19 item, we are delighted to take a step forward with Accelera in order to complete the regulatory documents essential for submitting the IMPD package.’ Enrico Pesenti, Handling Director at Accelera said: ‘The collaboration with Cellectis confirms Accelera exceptional competence in designing and executing preclinical programs with innovative biologicals and cell based therapies. The agreement can be a substantial sign of self-confidence in the excellent quality of the scientific and industrial study Nerviano Medical Sciences Group develops today.’..Details of the inclusion and exclusion requirements are given in the Supplementary Appendix. The investigator initial indicated which stenoses were thought to require stenting based on the scientific and angiographic data. FFR was after that measured with a coronary guidewire during adenosine-induced hyperemia to assess the hemodynamic severity of every indicated stenosis. Individuals who had at least one stenosis in a significant coronary artery with an FFR of 0.80 or much less were assigned randomly, through an interactive voice-response program, to FFR-guided PCI in addition to the best available medical therapy or to the best available medical therapy alone .